📰 Celularity Inc News
Page 13 - Celularity Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Celularity Inc. Real-time updates on events, politics, business and more.
June 18, 2022
NEW YORK, June 17, 2022 /PRNewswire/ -- The "Amniotic Membrane Market by Type and Geography - Forecast and Analysis 2021-2025" report has been added t
June 6, 2022
Sorrento Therapeutics (NASDAQ:SRNE – Get Rating) and Allogene Therapeutics (NASDAQ:ALLO – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends. Institutional and Insider Ownership 27.0% of Sorrento Therapeutics shares […]
June 3, 2022
Pharmaceutical and Biotech Industry Veteran Brings Significant Strategic Development and Commercialization Expertise Launching New Cellular Therapies...
May 25, 2022
Hariri Hall, a new dormitory in Yeh College, will welcome students in the fall of 2022.
May 17, 2022
/PRNewswire/ -- The "Global Amniotic Membrane Market 2022-2028" report has been added to ResearchAndMarkets.coms offering. As per the publishers report, the...
May 13, 2022
OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.30 A.M. ET).In the GreenEsports Technologies, Inc. (EBET) is up over 33% at $3.68 Affirm
May 9, 2022
Enochian Biosciences (NASDAQ:ENOB – Get Rating) and Celularity (NASDAQ:CELU – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk. Profitability This table compares Enochian Biosciences and Celularity’s net margins, […]
April 13, 2022
Equities research analysts expect Celularity Inc. (NASDAQ:CELU – Get Rating) to post earnings of ($0.23) per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Celularity’s earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.29). The company is scheduled to […]
April 7, 2022
Zacks Investment Research lowered shares of Celularity (NASDAQ:CELU – Get Rating) from a buy rating to a hold rating in a report published on Monday, Zacks.com reports. According to Zacks, “Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified […]
April 7, 2022
Celularity Inc. (NASDAQ:CELU – Get Rating)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $8.88, but opened at $8.62. Celularity shares last traded at $8.69, with a volume of 234 shares changing hands. A number of research analysts recently commented on CELU shares. Zacks Investment Research downgraded […]